Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy
Latest Information Update: 24 Jun 2024
Price :
$35 *
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 27 Jul 2023 Planned End Date changed from 17 Jul 2025 to 17 Jul 2029.
- 27 Jul 2023 Planned primary completion date changed from 17 Jul 2025 to 17 Jul 2029.
- 05 Jul 2023 Planned number of patients changed from 79 to 100.